ライフサイエンスコーパス: complement C3

1 us is dependent on innate immunity component complement C3.

2 iotensinogen, complement C4-A isoform 1, and complement C3.

3 inhibitors that bind and inhibit cleavage of complement C3.

4 lement regulators, and direct degradation of complement C3.

5 sing the expression and bacterial binding of complement C3.

6 ccus aureus protein that engages host Fg and complement C3.

7 their PNH erythrocytes become opsonized with complement C3.

8 o, processes strictly dependent on Mac-1 and complement C3.

9 uired for recognition of its natural ligand, complement C3d.

10 We investigated whether complement C3, a central component, affects synapse loss

11 We found that complement C3, a protein that is increased under inflamm

12 qa, factor B, and factor B/C2, we found that complement C3 activation and opsonophagocytosis of S. pn

13 (CRIg) and complement receptor 3 (CR3) after complement C3 activation at the bacterial surface.

14 membrane complement regulator that inhibits complement C3 activation by both classical and alternati

15 Complement C3 activation contributes to COVID-19 patholo

16 Complement C3 activation is a characteristic finding in

17 In our previous studies we showed that the complement C3 activation peptide, C3a, sensitizes respon

18 The ligation of the complement C3 activation product iC3b to complement rece

19 ike factor H, a potent negative regulator of complement C3 activation, the FHR proteins appear to pro

20 Following therapeutic inhibition of complement C3 activation, we found reduced myocardial up

21 lpha-synuclein increases occur downstream of complement C3 activation.

22 Intrinsic complement C3 activity is integral to human T helper typ

23 Thus, complement C3 allows cells to detect and disable pathoge

24 The role of mast cells, complement (C3 and C5a), and CD18 integrins in FcgammaRI

25 Plasma exchange, complement C3 and C3b inhibition, and rabbit anti-thymoc

26 ynapse pruning pathway, as mice deficient in complement C3 and C4 do not exhibit synapse elimination.

27 dy [ANA] and anti-double-stranded (ds) DNA), complement C3 and C4, and changes in renal and pulmonary

28 teases that carry the catalytic sites of the complement C3 and C5 convertases.

29 ologically active fragments derived from the complement C3 and C5 family of proteins.

30 (FcgammaRs), particularly FcgammaRIII, with complement C3 and C5 having no detectable role.

31 n the current study, we examined the role of complement C3 and C5 in sepsis in wild-type and C3- or C

32 lected periplakin, envoplakin, villin-1, and complement C3 and C9 for confirmation because they were

33 ons of both cell types through the C3:C3ar1 (complement C3 and Complement C3a receptor 1) axis.

34 Genetic deficiency of complement C3 and factor D prevented both the systemic t

35 ADAMTS5 and revealed specific proteolysis of complement C3 and fibronectin associated with IgA on imm

36 preventing interference by the glycoprotein complement C3 and its beta-globulin split products in th

37 Trypanosoma brucei interacts reversibly with complement C3 and its degradation products, but the mole

38 evealed an additional novel pathway in which complement C3 and its receptors enhance humoral immunity

39 ore, gut dysbiosis induces the expression of complement C3 and production of the anaphylatoxin C3a, a

40 human hepatocytes (huHep) eliminated murine complement C3 and reduced murine Kupffer cell density.

41 s nonhematopoietic in origin, independent of complement C3 and the adaptive immune system, mitigated

42 the discovery of a trypanosome receptor for complement C3 and we critically assess three recent stud

43 rostatic potential based on 24 homologues of complement C3d and 4 homologues of CR2.

44 CR2 ligands include complement C3d and Epstein-Barr virus glycoprotein 350/2

45 R-16/20 fragment possesses binding sites for complement C3d and heparin.

46 identify molecules with predicted binding to complement C3d and with intrinsic fluorescence propertie

47 um complement (C3), neointimal deposition of complement (C3d), and cellular composition (monocytes, m

48 oxidase, cathelicidin antimicrobial peptide, complement C3, and complement C5 were observed in early

49 of estrogen-responsive genes including pS2, complement C3, and progesterone receptor.

50 motif to bind to and inhibit the cleavage of complement C3, and small-angle X-ray scattering-based mo

51 treatment levels of natural antibody IgG1-4, complement C3, and/or C1q were significantly associated

52 ubset markers and for the third component of complement, C3, and membrane attack complex deposition.

53 atory tissue priming relies on intracellular complement C3- and C3a receptor-activation and downstrea

54 19-CD21 cell surface receptor complex, where complement C3d binding to CD21 supplies an already chara

55 ion of the B cell Ag receptor (BCR) with the complement (C3)-binding CD21/CD19/CD81 costimulatory com

56 ther the potential of an Ag to co-ligate the complement (C3d)-binding CD21 receptor complex with the

57 mice lacking Fcgamma receptors (FcgammaRs), complement (C3), both, or none.

58 Transgenic mice exhibited lower plasma complement C3 but increased deposition of CRP and C3 in

59 Complement C3 but not C5, and complement receptor CRIg b

60 Inhibition of complement C3 by CP40 (compstatin), C5 by eculizumab, or

61 Altering the electrophoretic behavior of complement C3, by treating fresh serum with inulin, perm

62 spiratory morbidity, growth, and anxiety and complement C3, C-reactive protein, serum cortisol, trans

63 l antibody (MAb) to type 3 capsule increases complement C3, C1q, and C4 deposition on WU2 and enhance

64 ment factor I (CFI), complement C9 (C9), and complement C3 (C3) genes.

65 Through microarray analysis, complement C3 (C3) was identified as one of the major ta

66 OH), alpha-1-acid glycoprotein 2 (ORM2), and complement C3 (C3), could be used for the discrimination

67 alpha1-antitrypsin [SERPINA1], 2.5-fold; and complement C3 [C3], 2.3-fold) and 5 were found to be dow

68 for subsequent vascular growth, through the complement C3/C3aR axis during neuroretinal development.

69 this work we investigated the impact of the complement C3/C3aR pathway on AHN and its functional imp

70 s one of the major binding partners of human complement C3/C3b components and their metabolites.

71 Covalent attachment of activated complement C3 (C3d) to antigen links innate and adaptive

72 tistically significant improvements in serum complement C3, C4, and anti-double-stranded DNA (anti-ds

73 imed at testing this idea for the paralogous complement C3, C4, and C5 proteins.

74 Levels of complement C3, C4, and CH50 and titers of anti-double-st

75 B cell memory response of mice deficient in complement C3, C4, or CD21/CD35 with wild-type controls.

76 owth factor beta, chemokine CCL2, SDF-1, and complements C3, C4, and factor B (CFB), were examined by

77 L, lactoferrin, macrophage-receptor-1, CD14, complement-c3/c4, xanthine dehydrogenase) than HoP.

78 ncreases in immunoglobulin (IgM and IgG) and complement (C3, C4d, and C5b-9) deposition, as well as w

79 teinuria levels correlated with staining for complement (C3, C5b-9) and IgG1 isotype in glomerular im

80 ytic pruning of post-synapses related to the complement C3 cascades during selective developmental st

81 Complement C3 cleavage products mediate the recognition

82 ophages capable of increased phagocytosis of complement C3-coated particles, a function critical for

83 s with IgAN, which contains higher levels of complement C3, compared to healthy individuals.

84 lysis or fibrinogen, C-reactive protein, and complement C3) confirmed that denser clots are independe

85 gents that target the alternative pathway of complement C3 convertase are being developed with a goal

86 n of decay-accelerating factor (DAF/CD55), a complement C3 convertase regulator, crucially controls d

87 cay-accelerating factor (DAF/CD55) and other complement C3 convertase regulators via BCL6, but increa

88 m short consensus repeats (SCRs), resembling complement C3 convertase regulators.

89 d a complex on the T. cruzi surface with the complement C3 convertase, leading to its stabilization a

90 ted antibodies, type I interferon (IFN), and complement C3, correlated with composite SLEDAI, but did

91 y included lipid transfer inhibitor protein, complement C3d, corticosteroid-binding globulin, apolipo

92 This study explored complement C3 deficiency in mice and human subjects for

93 Hereditary complement C3 deficiency is associated with recurrent ba

94 storation of virulence of the lctP mutant in complement (C3(-/-))-deficient animals.

95 control C57BL/6 (n=30) mice and into eyes of complement (C3)-deficient (n=15) or wild-type control 12

96 Following induction of BD in complement (C3)-deficient mice, cardiac troponin levels,

97 e role of C3 in AD pathology, we generated a complement C3-deficient amyloid precursor protein (APP)

98 Complement C3-deficient mice also had significantly decr

99 ated systemic LPS application was rescued in complement C3-deficient mice, confirming the involvement

100 - and Rac-independent pathways promote Mac-1/complement C3-dependent functions.

101 N-beta resulted in microglial activation and complement C3-dependent synapse elimination in vivo.

102 D18 integrin Mac-1 on neutrophils recognized complement C3 deposited within vessel walls and triggere

103 e mice had an increase in tubulointerstitial complement C3 deposition and neutrophil infiltration in

104 microenvironment, which results in prominent complement C3 deposition in kidney biopsy samples.

105 mmaRI-PspA-immunized Tg mice showed enhanced complement C3 deposition on bacterial surfaces, and prot

106 rocytes to macrophages are both dependent on complement C3 deposition onto the pneumococcal surface.

107 The enhanced complement C3 deposition realized in the absence of PspA

108 to human C4b and potently inhibits in vitro complement C3 deposition through the classical and lecti

109 PC, and CRP binding to pneumococci enhances complement C3 deposition through the classical pathway.

110 Complement C3 deposition was greatly attenuated in heart

111 dditionally, histopathology scores and total complement C3 deposition were significantly lower in Cl-

112 the K1 capsule, an increase in the level of complement C3 deposition, and an increase in both opsoni

113 ascular cellular infiltration; IgG, IgM, and complement (C3) deposition; vascular cell injury and int

114 Ab and complement (C3d) deposition was accompanied by extensive

115 Complement (C3d) deposition was diffuse and prominent in

116 Histologic quantification of complement C3 deposits in kidney biopsies provides progn

117 a have revealed that ASP is identical to the complement C3-derived activation peptide C3ades-Arg.

118 5) with human serum results in deposition of complement C3-derived polypeptides on virion particles.

119 maerase, Interceullular-adhesion-molecule-1, Complement C3, Dickkopf-WNT-signalling pathway-inhibitor

120 ng evidence that gain-of-function changes in complement C3 drive aHUS.

121 case of an adult with complete deficiency of complement C3 due to homozygous mutations in C3 gene: c.

122 dy production was observed in the absence of complement C3 during infection.

123 The role of the third component of complement (C3) during schistosome infection was investi

124 receptor that binds three distinct ligands (complement C3d, Epstein-Barr virus gp350/220, and the lo

125 cluding soluble sTREM2 levels in the CSF and complement C3 expression in the blood transcriptome.

126 in both microglia and astrocytes and raised complement C3 expression on astrocytes, all consistent w

127 of NTRK1 signaling in tumor cells increased complement C3 expression, which enhanced the recruitment

128 Pups deficient in complement (C3-/-) failed to recruit neutrophils and did

129 PASP was found to degrade complement C3, fibrinogen, antimicrobial peptide LL-37,

130 complexes, and glomerular deposition of IgA, complement C3, Fn and collagen.

131 omplement receptor type 2 (CR2) that bind to complement C3d, followed by the first five SCR domains o

132 to intercellular adhesion molecule (ICAM)-1, complement C3 fragment iC3b, and fibronectin, and potent

133 on MCF7 inhibited the in vivo deposition of complement C3 fragments that serve as opsonins for recep

134 Using a membrane-bound complement C3 fusion protein, we demonstrate that enhanc

135 ly recognize and respond to antigens bearing complement C3d(g).

136 e located on the sense DNA strand within the complement C3 gene locus which is encoded on the antisen

137 The analysis of the human complement C3 gene reveals the presence of functional FX

138 ts carrying the same mutation, R139W, in the complement C3 gene.

139 The expression of complement C3 (>5-fold) and CFB (>30-fold) genes in the

140 ns of the activating components factor B and complement C3 have also been reported.

141 emonstrate that the majority of mutations in complement C3 identified in atypical hemolytic uremic sy

142 Intragraft immunoglobulin G (IgG) and complement C3 immunostaining were compared among allogen

143 ciated serine protease-2 can activate native complement C3 in absence of C4 and/or C2.

144 following IOP elevation is up-regulation of complement C3 in astrocytes of DBA/2J and DBA/2J.Wld(s)

145 study, our goal was to ascertain the role of complement C3 in autoimmune diabetes.

146 The role of complement C3 in mediating systemic lupus erythematosus

147 Our results suggest a beneficial role for complement C3 in plaque clearance and neuronal health as

148 The presence of complement C3 in serum promoted phagocytosis, yet phagos

149 ermined deficiency of the third component of complement (C3) in the dog is characterized by a predisp

150 Enhanced complement C3 incorporation into the fibrin network in d

151 Ib and bacterial opsonization with activated complement C3, influences blood clearance and anti-infec

152 Complement C3 inhibition with compstatin Cp40 disrupted

153 oss and thinning are reduced by intravitreal complement C3 inhibition.

154 sessed the association of treatment with the complement C3 inhibitor pegcetacoplan with optical coher

155 With the addition of the compstatin-based complement C3 inhibitor pegcetacoplan, another class of

156 the safety and efficacy of pegcetacoplan, a complement C3 inhibitor, for treatment of GA.

157 In the PEGASUS trial, the complement C3 inhibitor, pegcetacoplan, showed superiori

158 ta support the strategy of using recombinant complement C3 inhibitors to treat human lupus nephritis.

159 ition, pathogens carried covalently attached complement C3 into the cell, triggering immediate signal

160 Complement C3 is a pivotal component of three cascades o

161 Complement C3 is important for the classical, alternativ

162 Complement C3 is important in the pathogenesis of age-re

163 Complement C3 is positioned as a central player that rel

164 Complement C3 is required for intravascular clearance of

165 Complement C3 is usually present in both.

166 , the functionally active third component of complement (C3) is encoded by a single gene.

167 The third component of complement, C3, is a point of convergence of distinct co

168 ion, the chemokines CXCL1, CXCL5, CXCL6, and complement C3, known to contribute to chronic inflammati

169 % used either the anti-DNA antibody level or complement C3 level to monitor patients with SLE, and 95

170 m hemolytic complement (CH(50)) activity and complement C3 levels during infection, and serum opsonic

171 Serum IgG1-3 and complement C3 levels were significantly higher in HBeAg-

172 erminal center formation and decreased serum complement C3 levels.

173 ctive target at or near the TEP1 gene, whose complement C3-like product has antiparasitic and antibac

174 The complex interacts with the complement C3-like protein, TEP1, promoting its cleavage

175 -acid glycoprotein 1, alpha-2-macroglobulin, complement C3, mannose-binding protein C, and major urin

176 The subsequent maturation complement C3 maturation to anaphylatoxin C3a was depend

177 rs sensitivity to immunotherapy by enhancing complement C3-mediated T-cell and macrophage functions,

178 lement-dependent, since it was attenuated in complement C3(-/-) mice and by injection of C5-blocking

179 Levels of serum complement (C3), neointimal deposition of complement (C3

180 characterized by electron-dense deposits and complement C3 on the glomerular basement membrane.

181 and antibodies to PspA on the deposition of complement C3 on the surface of a capsular type 3 strain

182 ed for efficient binding and phagocytosis of complement C3-opsonized particles.

183 ciency in IL-34 production) or deficiency in complement C3 or C3a receptor were protected from WNV-in

184 A trend toward normal complement C3 or C4 level at week 26 was seen in the sif

185 Genetic ablation of complement C3 or its inactivation with Cobra Venom Facto

186 t mutant in regard to avid binding by murine complement C3 or resistance to serum- or whole-blood-med

187 Our results suggest that complement C3, or its downstream signaling, is detriment

188 ificantly decreased alpha2-macroglobulin and complement C3, P < 0.05.

189 of transcripts for the APPs serum amyloid A, complement C3, pentraxin 3, and alpha2-antiplasmin in th

190 The third component of human complement (C3) plays a central role in innate immune fu

191 P-2.DNA complex formation, and for the human complement C3 promoter, overexpression of AP-2 also coul

192 of infertility with significantly increased complement C3 protein deposition in the testes, accompan

193 We evaluated complement C3 protein deposition on discordant S. pneumo

194 t an increase in the plasma concentration of complement C3 protein.

195 eta receptor (IFNAR) and is inhibited by the complement C3 protein.

196 ntified a 20-kDa protein with putative human complement C3-proteolytic activity.

197 CRIg is a recently discovered complement C3 receptor expressed on a subpopulation of t

198 Ig superfamily (CRIg), a recently discovered complement C3 receptor.

199 ic complement pathway despite an increase in complement C3 regulatory proteins.

200 ctivation induced by dsRNA in mice, an acute complement C3 response was seen at 2 days.

201 r kappaB (NF-kappaB)-dependent signaling and complement C3 secretion.

202 of the process by detecting the presence of complement C3, SHC-transforming protein 1, and kininogen

203 veal the therapeutic value of inhibiting the complement C3 signaling pathway in NMO.

204 Peritubular complement C3d staining was also similar in both groups.

205 us pneumoniae to bind the third component of complement (C3) suggests possible interactions with opso

206 Using this method, we found that anti-complement C3-targeted ultrasmall superparamagnetic iron

207 e previously reported that rats deficient in complement C3, the central component of complement activ

208 posure resulted in production and release of complement C3, the generation of C3a, oxidative stress,

209 ological activities, including a fragment of complement C3, the spasmogenic C3f, which was processed

210 get pathological neovasculature and activate complement (C3), thereby inducing neovascularitis, infil

211 Disease activity scores, complement C3 tissue deposition in the joint, and histop

212 and decreasing the third component of serum complement (C3) to be associated with increasing glomeru

213 inear deposits of immunoglobulin G (IgG) and complement C3, typical of anti-glomerular basement membr

214 alpha-1-antitrypsin, pancreatic polypeptide, complement C3, vitronectin, cortisol, AXL receptor kinas

215 Complement C3 was the dominant gene targeted by TLR9-ind

216 In addition, mouse complement (C3) was detected on xenografted PI.

217 ns capable of binding the third component of complement (C3), we coupled the free sulfhydryl group of

218 Furthermore, mice deficient in complement C3 were resistant to fetal injury induced by

219 d an adjuvant effect for the C3d fragment of complement C3 when coupled to T-dependent protein antige

220 ppa B (NF-kappaB), leading to the release of complement C3, which acts on the neuronal C3a receptor (

221 This system centres around complement C3, which is present in a soluble form in ser

222 lized in the synovial lining area along with complement C3 while FH was almost undetectable in the sy

223 ulopathy is characterized by accumulation of complement C3 within glomeruli.

224 tein (FHR5mut) that leads to accumulation of complement C3 within glomeruli.